Tokai Pharmaceuticals Inc. called off a pivotal phase III trial comparing its triple-acting prostate cancer drug, galeterone, to Xtandi (enzalutamide, Medivation Inc.) after a data monitoring committee determined the trial was unlikely to meet its primary endpoint.